Navigation Links
BD Announces 2011 Analyst Day and Webcast
Date:10/28/2011

FRANKLIN LAKES, N.J., Oct. 28, 2011 /PRNewswire/ --  BD (Becton, Dickinson and Company) (NYSE: BDX) announced today that it will host an institutional investor and analyst meeting on Wednesday, November 9, 2011, in New York City from 7:45 a.m. – 12:45 p.m. (ET).  The meeting will update the investment community on BD's corporate strategy, focusing on investing and innovating for growth.  

Live webcasts of the 90-minute General Session at 7:45 a.m. and the 30-minute Q & A Session at 12:15 p.m. will be accessible through BD's website at www.bd.com/investors.  A replay of the webcasts will be available through Wednesday, November 16, 2011.  

About BD

BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 29,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit www.bd.com.

Contact:

Monique N. Dolecki, Investor Relations – 201-847-5378
Colleen T. White, Corporate Communications – 201-847-5369


'/>"/>
SOURCE BD (Becton, Dickinson and Company)
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related medicine technology :

1. ZONARE Medical Systems Announces Appointment of PJ Ryland as Vice President of Business Development & Corporate Accounts
2. Valeant Announces Take-Up of Additional Afexa Shares and Special Meeting of Shareholders of Afexa to Approve Its Privatization
3. Halozyme Therapeutics Announces Positive Results From Enzyme-Augmented Insulin Pump Trial
4. HeartWare International Announces Planned Departure of Chief Financial Officer
5. Omnicell Announces Third Quarter 2011 Results
6. Cardica Announces Fiscal 2012 First Quarter Financial Results
7. BioMarin Announces Third Quarter 2011 Financial Results
8. IRIDEX Announces Third Quarter 2011 Conference Call and Release Date
9. Span-America Announces Fourth Quarter and Fiscal Year-End 2011 Conference Call on the Internet
10. Vapotherm® Announces FDA Clearance for Precision Flow® Heliox System
11. China Kanghui Holdings Announces Participation in Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... , May 21, 2013   Accuray Incorporated ... the publication of study results involving hundreds of ... Radiosurgery System, the most widely used form of ... followed 304 patients for a median of 5 ... found that 97 percent of patients with low-risk ...
(Date:5/21/2013)...  Janssen R&D Ireland (Janssen) today announced primary ... 3 PROMISE study demonstrating that use of the ... virologic response 12 weeks after the end of ... 1 chronic hepatitis C adult patients with compensated ... when administered once daily with pegylated interferon and ...
(Date:5/21/2013)... , May 21, 2013 Abaxis, Inc. (NasdaqGS: ... systems, announced today that Martin Mulroy ... Stifel Annual Dental & Veterinary Conference on Wednesday, May ... be held at Le Parker Meridien Hotel in ... Abaxis Abaxis develops, manufactures, markets and sells ...
Breaking Medicine Technology:New Data Validates CyberKnife SBRT for Prostate Cancer Treatment 2New Data Validates CyberKnife SBRT for Prostate Cancer Treatment 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 2Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 4Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 5Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 6Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 7Abaxis, Inc. to Present at the Stifel Annual Dental & Veterinary Conference 2
(Date:5/21/2013)... (PRWEB) May 21, 2013 MedMar Healing ... drive to benefit Second Harvest Food Bank. Twenty-eight businesses, including ... participate in the food drive. The goal is to raise ... the economic problems facing their families in recent years. ... community and help those in need,” explains Douglas Chloupek of ...
(Date:5/21/2013)... recently published in the New England Journal of ... the University of Colorado School of Medicine finds that ... be used to identify individuals at risk for this ... common variant of the gene for mucin-5B, a protein ... the bronchial tubes. While this variant of the MUC5B ...
(Date:5/21/2013)... Research into genetic features of pulmonary fibrosis by ... of Medicine may lead to improved treatment of this ... by JAMA . , The study found that ... cases of pulmonary fibrosis, a chronic progressive disease with ... of the study, researchers may want to consider including ...
(Date:5/21/2013)... and technological research So Paulo Research Foundation, FAPESP, based ... estimated in US$ 680 million to support 17 Research, ... up to eleven years, subject to continuation reviews on ... the 17 RIDCs will come from FAPESP and the ... infrastructure). Host institutions will participate in a portion of ...
(Date:5/21/2013)... York (PRWEB) May 21, 2013 The ... robot lawsuit is nearing its conclusion in Washington ... Bloomberg.com, during closing statements yesterday, an attorney for the ... the company wanted to tie sales and services for ... the training to keep control of surgeons, to keep ...
Breaking Medicine News(10 mins):Health News:San Jose Cannabis Club Helps Feed Hungry Children with Second Harvest Food Bank 2Health News:Researchers find genetic risk factor for pulmonary fibrosis 2Health News:Researchers find genetic tie to improved survival time for pulmonary fibrosis 2Health News:Research at the cutting edge of knowledge 2Health News:Da Vinci Surgery Robot Lawsuit News: Bernstein Liebhard LLP Comments on Closing Arguments in Nation’s First Da Vinci Lawsuit Trial 2Health News:Da Vinci Surgery Robot Lawsuit News: Bernstein Liebhard LLP Comments on Closing Arguments in Nation’s First Da Vinci Lawsuit Trial 3Health News:Da Vinci Surgery Robot Lawsuit News: Bernstein Liebhard LLP Comments on Closing Arguments in Nation’s First Da Vinci Lawsuit Trial 4
... ... PhD, JD, is Keynote Speaker on the Failed War on Drugs , ... Las Vegas, NV (PRWEB) September 11, 2009 -- ... Drug Policy Alliance advocating for drug reform in the United States as keynote speaker former ...
... acoustic neuromas , FRIDAY, Sept. 11 (HealthDay News) -- Last ... or the sound of a dog barking. She was 22. ... type 2 (NF2), a condition characterized by tumors in the ... cranial nerve in one ear. , The result: increasing hearing ...
... affects insulin resistance, study finds, , FRIDAY, Sept. 11 (HealthDay ... insight into type 2 diabetes, potentially leading to better treatment ... appears to be linked to diabetes, affects how the body ... published Sept. 6 in Nature Genetics . , "Most ...
... Duane Reade Holdings Inc., the largest drug store in metropolitan New ... 2009 Komen New York City Race For The Cure, the Company, ... raised $330,000 to increase awareness of breast cancer and to assist ... year that Duane Reade has proudly sponsored this momentous event, with ...
... , , MADISON, N.J. and ... (FDA) today cleared the OVA1(TM) Test, the first blood test that, ... at risk for a malignant pelvic mass. OVA1 is the first ... with high sensitivity prior to biopsy or exploratory surgery, even if ...
... , , , ... Gardasil, declined by a third this year, and three years after ... women remain unvaccinated -- despite millions spent on advertising and lobbying ... , , Michelle Steward, assistant professor of marketing ...
Cached Medicine News:Health News:Healthcare Legal Issues Take the Stage at PAINWeek 2009 2Health News:Healthcare Legal Issues Take the Stage at PAINWeek 2009 3Health News:Cancer Drug Shrinks Benign Tumors That Steal Hearing 2Health News:Cancer Drug Shrinks Benign Tumors That Steal Hearing 3Health News:New Yorkers Help Duane Reade Increase Support of the 19th Annual Komen New York City Race For The Cure(R) 2Health News:New Yorkers Help Duane Reade Increase Support of the 19th Annual Komen New York City Race For The Cure(R) 3Health News:U.S. Food and Drug Administration Clears Vermillion's OVA1(TM) Test to Determine Likelihood of Ovarian Cancer in Women with Pelvic Mass 2Health News:U.S. Food and Drug Administration Clears Vermillion's OVA1(TM) Test to Determine Likelihood of Ovarian Cancer in Women with Pelvic Mass 3Health News:U.S. Food and Drug Administration Clears Vermillion's OVA1(TM) Test to Determine Likelihood of Ovarian Cancer in Women with Pelvic Mass 4Health News:U.S. Food and Drug Administration Clears Vermillion's OVA1(TM) Test to Determine Likelihood of Ovarian Cancer in Women with Pelvic Mass 5Health News:HPV Vaccine Study Shows Why Few Women Getting Shots 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: